Ayahuasca, a traditional medicine from the Amazon rainforest, has shown promising effects in treating mental health issues. In a sample of 120 participants, 70% reported significant reductions in anxiety and depression after just one session. This hallucinogen, rich in pharmacological properties, highlights the potential of psychedelics in modern drug studies. As interest grows alongside cannabis and cannabinoid research, biochemical analysis reveals ayahuasca's unique compounds may offer new avenues for therapeutic applications, bridging indigenous practices with contemporary medicine.
Major depression increases the risk of later dementia, and late-life depression may be an early sign of dementia. Adult hippocampal neurogenesis (AHN), the lifelong birth of new neurons in the dentate gyrus, supports learning, memory, and mood. Microglia, the brain's immune cells, regulate AHN, and disruptions in AHN and microgliosis are linked to both depression and neurodegenerative diseases. Psychedelics like psilocybin, a serotonergic agonist with rapid antidepressant effects, may promote neuroplasticity and modulate microglial function. This narrative review examines evidence that psilocybin could affect AHN and microglia, potentially altering the progression from major depression to dementia in at-risk individuals.